186 related articles for article (PubMed ID: 15148490)
1. Graft-versus-host disease of the skin: life and death on the epidermal edge.
Hofmeister CC; Quinn A; Cooke KR; Stiff P; Nickoloff B; Ferrara JL
Biol Blood Marrow Transplant; 2004 Jun; 10(6):366-72. PubMed ID: 15148490
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
4. The changing face of graft-versus-host disease.
Schaffer JV
Semin Cutan Med Surg; 2006 Dec; 25(4):190-200. PubMed ID: 17174839
[TBL] [Abstract][Full Text] [Related]
5. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
[TBL] [Abstract][Full Text] [Related]
6. Skin explant model of human graft-versus-host disease: prediction of clinical outcome and correlation with biological risk factors.
Wang XN; Collin M; Sviland L; Marshall S; Jackson G; Schulz U; Holler E; Karrer S; Greinix H; Elahi F; Hromadnikova I; Dickinson AM
Biol Blood Marrow Transplant; 2006 Feb; 12(2):152-9. PubMed ID: 16443513
[TBL] [Abstract][Full Text] [Related]
7. GVHD after chemotherapy conditioning in allogeneic transplanted mice.
Sadeghi B; Aghdami N; Hassan Z; Forouzanfar M; Rozell B; Abedi-Valugerdi M; Hassan M
Bone Marrow Transplant; 2008 Dec; 42(12):807-18. PubMed ID: 18820712
[TBL] [Abstract][Full Text] [Related]
8. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
[TBL] [Abstract][Full Text] [Related]
9. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
10. Colonic graft-versus-host disease.
Ross WA; Couriel D
Curr Opin Gastroenterol; 2005 Jan; 21(1):64-9. PubMed ID: 15687887
[TBL] [Abstract][Full Text] [Related]
11. Keratinocyte apoptosis following bone marrow transplantation: evidence for CTL-dependent and -independent pathways.
Jerome KR; Conyers SJ; Hansen DA; Zebala JA
Bone Marrow Transplant; 1998 Aug; 22(4):359-66. PubMed ID: 9722071
[TBL] [Abstract][Full Text] [Related]
12. Partial reconstitution of cutaneous microvessels in long-term survivors after allogeneic bone marrow transplantation.
Haeusermann P; Kump E; Rovó A; Tichelli A; Itin P; Gratwohl A; Biedermann BC
Dermatology; 2009; 219(1):32-41. PubMed ID: 19407437
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
[TBL] [Abstract][Full Text] [Related]
14. [Graft vs host disease].
Moalic V; Ferec C
Pathol Biol (Paris); 2006 May; 54(5):304-8. PubMed ID: 16530350
[TBL] [Abstract][Full Text] [Related]
15. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
[TBL] [Abstract][Full Text] [Related]
16. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
17. Life-threatening graft-vs-host disease.
Vargas-Díez E; García-Díez A; Marín A; Fernández-Herrera J
Clin Dermatol; 2005; 23(3):285-300. PubMed ID: 15896544
[TBL] [Abstract][Full Text] [Related]
18. [Graft versus host disease and cytokines].
Itoh T
Nihon Rinsho; 2003 Sep; 61(9):1504-11. PubMed ID: 14515716
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous graft-versus-host disease: a guide for the dermatologist.
Häusermann P; Walter RB; Halter J; Biedermann BC; Tichelli A; Itin P; Gratwohl A
Dermatology; 2008; 216(4):287-304. PubMed ID: 18230976
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
Auletta JJ; Cooke KR
Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
